“Valeant's Legal Woes Aren't New, but They Are Mounting,” The Motley Fool
August 16, 2016
The list of investigations into the company is getting longer.
On the heels of a dramatic post-second quarter earnings run-up in shares, reports of a federal criminal investigation into its past business dealings has Valeant Pharmaceuticals (NYSE:VRX) investors back on the defense again. The reports of investigations into the company's use of Philidor (a specialty pharmacy it was closely tied to) aren't new, but the number of investigations does appear to be increasing, and that adds uncertainty to a story that was already pretty uncertain.
